AMPH vs. FPRX, PTGX, SNDX, DYN, CALT, INSM, ASND, CERE, LEGN, and ITCI
Should you be buying Amphastar Pharmaceuticals stock or one of its competitors? The main competitors of Amphastar Pharmaceuticals include Five Prime Therapeutics (FPRX), Protagonist Therapeutics (PTGX), Syndax Pharmaceuticals (SNDX), Dyne Therapeutics (DYN), Calliditas Therapeutics AB (publ) (CALT), Insmed (INSM), Ascendis Pharma A/S (ASND), Cerevel Therapeutics (CERE), Legend Biotech (LEGN), and Intra-Cellular Therapies (ITCI). These companies are all part of the "medical" sector.
Five Prime Therapeutics (NASDAQ:FPRX) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.
Amphastar Pharmaceuticals has a net margin of 22.88% compared to Amphastar Pharmaceuticals' net margin of -554.71%. Five Prime Therapeutics' return on equity of 29.17% beat Amphastar Pharmaceuticals' return on equity.
67.3% of Five Prime Therapeutics shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 6.4% of Five Prime Therapeutics shares are owned by company insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Five Prime Therapeutics has a beta of 4.4, suggesting that its stock price is 340% more volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.
In the previous week, Amphastar Pharmaceuticals had 7 more articles in the media than Five Prime Therapeutics. MarketBeat recorded 7 mentions for Amphastar Pharmaceuticals and 0 mentions for Five Prime Therapeutics. Five Prime Therapeutics' average media sentiment score of 0.93 beat Amphastar Pharmaceuticals' score of 0.00 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.
Amphastar Pharmaceuticals received 81 more outperform votes than Five Prime Therapeutics when rated by MarketBeat users. Likewise, 66.67% of users gave Amphastar Pharmaceuticals an outperform vote while only 55.86% of users gave Five Prime Therapeutics an outperform vote.
Amphastar Pharmaceuticals has higher revenue and earnings than Five Prime Therapeutics. Five Prime Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Amphastar Pharmaceuticals has a consensus price target of $66.00, indicating a potential upside of 62.12%. Given Five Prime Therapeutics' higher possible upside, analysts plainly believe Amphastar Pharmaceuticals is more favorable than Five Prime Therapeutics.
Summary
Amphastar Pharmaceuticals beats Five Prime Therapeutics on 14 of the 17 factors compared between the two stocks.
Get Amphastar Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amphastar Pharmaceuticals Competitors List
Related Companies and Tools
